CoChat

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Summary: Background This open-label, first-in-human, phase 1 study evaluated AMG 232, an oral selective MDM2 inhibitor in patients with TP53 wild-type (P53WT), advanced solid tumors or multiple myeloma (MM). Methods In the dose escalation ( n = 39), patients with P53WT refractory solid tumors enrolled to receive once-daily AMG 232 (15, 30, 60, 120, 240, 480, and 960 mg) for seven days every 3 weeks (Q3W). In the dose expansion ( n = 68), patients with MDM2 -amplified (well-differentiated and de-differentiated liposarcomas [WDLPS and DDLPS], glioblastoma multiforme [GBM], or other solid tumors [OST]), MDM2-overexpressing ER+ breast cancer (BC), or MM received AMG 232 at the maximum tolerated dose (MTD). Safety, pharmacokinetics, pharmacodynamics, and efficacy were assessed. Results AMG 232 had acceptable safety up to up to 240 mg. Three patients had dose-limiting toxicities of thrombocytopenia ( n = 2) and neutropenia ( n = 1). Due to these and other delayed cytopenias, AMG 232 240 mg Q3W was determined as the highest tolerable dose assessed in the dose expansion. Adverse events were typically mild/moderate and included diarrhea, nausea, vomiting, fatigue, decreased appetite, and anemia. AMG 232 plasma concentrations increased dose proportionally. Increases in serum macrophage inhibitor cytokine-1 from baseline were generally dose dependent, indicating p53 pathway activation. Per local review, there were no responses. Stable disease (durability in months) was observed in patients with WDLPS (3.9), OST (3.3), DDLPS (2.0), GBM (1.8), and BC (1.4–2.0). Conclusions In patients with P53WT advanced solid tumors or MM, AMG 232 showed acceptable safety and dose-proportional pharmacokinetics, and stable disease was observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10637-019-00840-1

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mean (± SD) pharmacokinetic profile of AMG 232 following oral administration every 3 weeks in the dose escalation (a) and in the dose expansion (b). DDLPS, dedifferentiated liposarcoma; GBM, glioblastoma multiforme; OST, other solid tumor; WDLPS, well differentiated liposarcoma
Fig. 1 Mean (± SD) pharmacokinetic profile of AMG 232 following oral administration every 3 weeks in the dose escalation (a) and in the dose expansion (b). DDLPS, dedifferentiated liposarcoma; GBM, glioblastoma multiforme; OST, other solid tumor; WDLPS, well differentiated liposarcomaCC BY · PubMed Central
Fig. 2 Mean (± SE) ratio of post-treatment versus pre-treatment serum MIC-1 in the dose escalation
Fig. 2 Mean (± SE) ratio of post-treatment versus pre-treatment serum MIC-1 in the dose escalationCC BY · PubMed Central
Fig. 3 Best change from baseline in the sum of longest diameters of target lesions in the dose escalation (a) and in the dose expansion (b). ACC, adenoid cystic carcinoma; CAC, cholangiocarcinoma; Chondro, chondrosarcoma; DDLPS, dedifferentiated liposarcoma; Esoph, esophageal; GBM, glioblastoma multiforme; GPL, glandular parotis left; Gran, granular cell tumor; Leio, leiomyosarcoma; Mel, melanoma; Neuro, neuroendocrine; NSCLC, non–small-cell lung cancer; OST, other solid tumor; Panc, pancreatic; Pleural, pleural mesothelioma; Saliv, salivary gland; SCCHN, squamous cell carcinoma of the head and neck; SFT, solitary fibrous tumor; STS, soft tissue sarcoma; WDLPS, well differentiated liposarcoma. *Patient had partial response per central review
Fig. 3 Best change from baseline in the sum of longest diameters of target lesions in the dose escalation (a) and in the dose expansion (b). ACC, adenoid cystic carcinoma; CAC, cholangiocarcinoma; Chondro, chondrosarcoma; DDLPS, dedifferentiated liposarcoma; Esoph, esophageal; GBM, glioblastoma multiforme; GPL, glandular parotis left; Gran, granular cell tumor; Leio, leiomyosarcoma; Mel, melanoma; Neuro, neuroendocrine; NSCLC, non–small-cell lung cancer; OST, other solid tumor; Panc, pancreatic; Pleural, pleural mesothelioma; Saliv, salivary gland; SCCHN, squamous cell carcinoma of the head and neck; SFT, solitary fibrous tumor; STS, soft tissue sarcoma; WDLPS, well differentiated liposarcoma. *Patient had partial response per central reviewCC BY · PubMed Central
Fig. 4 Duration of stable disease in the dose escalation (a) and in the dose expansion (b). DDLPS, dedifferentiated liposarcoma; GBM, glioblastoma multiforme; OST, other solid tumor; WDLPS, well differentiated liposarcoma
Fig. 4 Duration of stable disease in the dose escalation (a) and in the dose expansion (b). DDLPS, dedifferentiated liposarcoma; GBM, glioblastoma multiforme; OST, other solid tumor; WDLPS, well differentiated liposarcomaCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 140

Metadata

Authors
Gluck, W. L., Gounder, M. M., Frank, R., Eskens, F., Blay, J. Y., Cassier, P. A., Soria, J.-C., Chawla, S., de Weger, V., Wagner, A. J., Siegel, D., De Vos, F., Rasmussen, E., & Henary, H. A.
Affiliations
  • Prisma Health (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Norwalk Hospital (US)
  • Erasmus MC Cancer Institute (NL)
  • Centre Léon Bérard (FR)
  • Université Paris-Sud (FR)
  • Sarcoma Oncology Center (US)
  • Harvard University (US)
  • Hackensack University Medical Center (US)
  • Amgen (United States) (US)
Corresponding author
Gluck, W. Larry
Venue
Investigational New Drugs
Published
2019-07-29
Volume
38
Issue
3
Pages
831-843
ISSN
  • 0167-6997 (ISSN-L)
  • 1573-0646
OpenAlex
W2965547724
Cited by
127
References
37
Citations by year
2026: 9 · 2025: 22 · 2024: 26 · 2023: 20 · 2022: 19 · 2021: 25 · 2020: 3 · 2019: 2
FWCI
5.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Investigational New Drugs (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
Funders
Amgen
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords
MDM2 inhibitors, wild-type p53, multiple myeloma, advanced solid tumors, liposarcoma, glioblastoma, estrogen receptor-positive breast cancer, MDM2 amplification, MDM2 overexpression, thrombocytopenia, neutropenia, dose-limiting toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose
MeSH terms
Acetates, Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Multiple Myeloma, Piperidones, Tumor Suppressor Protein p53, Maximum Tolerated Dose, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. https://app.cochat.ai/papers/10.1007/s10637-019-00840-1
The paper
Gluck, W. L., Gounder, M. M., Frank, R., Eskens, F., Blay, J. Y., Cassier, P. A., Soria, J.-C., Chawla, S., de Weger, V., Wagner, A. J., Siegel, D., De Vos, F., Rasmussen, E., & Henary, H. A. (2020). Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Investigational New Drugs. https://doi.org/10.1007/s10637-019-00840-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.